Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imetelstat + Fludarabine + Cytarabine in Relapsed/Refractory AML, MDS, or JMML
NCT06247787Phase 1Recruiting
- Sponsor
- Children's Oncology Group
- Start
- Feb 2025
- Primary completion
- Mar 2028
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of imetelstat in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML), sponsored by Children's Oncology Group. Primary endpoint: Dose limiting toxicities at 4 weeks. Started Feb 2025; status: recruiting.
02
Drugs
imetelstat
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)juvenile myelomonocytic leukemia (JMML)
Beyond the preview
Go deeper on NCT06247787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06247787.